Gliomas are the most common central nervous system tumors. New technologies, including
genetic research and advanced statistical methods, revolutionize the therapeutic approach …

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an
exceedingly low median overall survival of only 15 months. Current standard-of-care for …

Glioblastoma, the most aggressive form of malignant glioma, is very difficult to treat because
of its aggressively invasive nature and high recurrence rates. RAS‐selective lethal 3 (RSL3) …

Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy
for glioblastoma multiforme (GBM) and astrocytoma. A majority of patients do not respond to …

Glioblastoma (GBM) is a highly malignant brain tumor characterized by a heterogeneous
population of genetically unstable and highly infiltrative cells that are resistant to …

Background Temozolomide (TMZ) resistance limits its application in glioma. Exosome can
carry circular RNAs (circRNAs) to regulate drug resistance via sponging microRNAs …

Simple Summary Despite the continuous development of treatment technology,
glioblastoma remains a challenge for modern medicine. The standard of care remains a …

Exosome-mediated delivery of circular RNAs (circRNAs) is implicated in cancer progression.
However, the role of exosomal circRNAs in the chemotherapy resistance of tumours remains …

It has been demonstrated from previous studies about the killing effect of dihydroartemisinin
(DHA) on glioblastoma, which involves multiple aspects: cytotoxicity, cell cycle arrest and …

The prognosis of brain cancers such as glioblastoma remains poor despite numerous
advancements in the field of neuro-oncology. The presence of the blood brain barrier (BBB) …